Citizens Maintains Market Outperform on Mirum Pharmaceuticals, Raises Price Target to $146

Benzinga Newsdesk www.benzinga.com Positive 92.0%

Neg 0% Neu 0% Pos 92%

Citizens analyst Jonathan Wolleben maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Market Outperform and raises the price target from $140 to $146.